Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

[1]  A. Gross,et al.  Single application of high‐intensity focused ultrasound as a first‐line therapy for clinically localized prostate cancer: 5‐year outcomes , 2012, BJU international.

[2]  F. Farrokhyar,et al.  Single‐session primary high‐intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation‐based technology , 2012, BJU international.

[3]  X. Rébillard,et al.  Correlation of prostate‐specific antigen nadir and biochemical failure after high‐intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria – analysis from the @‐Registry , 2011, BJU international.

[4]  S. Crouzet,et al.  Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. , 2010, European urology.

[5]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  V. Seshan,et al.  Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. , 2009, International journal of radiation oncology, biology, physics.

[7]  J. Eastham,et al.  High‐intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure , 2009, BJU international.

[8]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  Bernhard Walter,et al.  First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. , 2008, European urology.

[10]  X. Rébillard,et al.  High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology , 2008, BJU international.

[11]  M. Schostak,et al.  PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. , 2008, European urology.

[12]  A. Hanlon,et al.  Timing of biochemical failure and distant metastatic disease for low‐, intermediate‐, and high‐risk prostate cancer after radiotherapy , 2007, Cancer.

[13]  M. Emberton,et al.  To what extent does the prostate‐specific antigen nadir predict subsequent treatment failure after transrectal high‐intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? , 2006, BJU international.

[14]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[15]  M. Peyromaure,et al.  [Follow-up of prostate cancer. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie]. , 2005, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[16]  D. Kuban,et al.  Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. , 2005, The Journal of urology.

[17]  D. Kuban,et al.  Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. , 2003, International journal of radiation oncology, biology, physics.

[18]  D. Hussey.  American Society for Therapeutic Radiology and Oncology , 2001 .

[19]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[20]  J. Dekernion,et al.  Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. , 1997, The Journal of urology.

[21]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[22]  M. Peyromaure,et al.  Suivi du cancer de la prostate , 2005 .

[23]  Prostate cancer. NCCN clinical practice guidelines in oncology. , 2004, Journal of the National Comprehensive Cancer Network : JNCCN.